奎硫平单用与合并阿立哌唑对精神分裂症患者体质量的影响

Effects of quetiapine only and combined with aripiprazole on the body mass of patients with schizophrenia

目的:探讨奎硫平与阿立哌唑合用及单用奎硫平对精神分裂症患者体质量、腹围及体质量指数(BMI)的影响。方法:将63例精神分裂症患者随机分为阿立哌唑合并奎硫平组31例(研究组)及单用奎硫平组32例(对照组)。在治疗前及治疗6周,用阳性和阴性症状量表(PANSS)评定疗效,并进行体质量、腹围及BMI的测定。结果:治疗6周两组PANSS评分差异无统计学意义(t=1.35,P>0.05);研究组治疗后腹围值增加明显(t=7.76,P<0.05),对照组体质量、腹围及BMI值均增加明显(P<0.05);组间变化值的比较体质量、腹围及BMI增加值均较对照组小(P<0.05)。

Objective： To explore the effects of quetiapine only and combined with aripiprazole on the body mass,abdominal girth and body mass index （BMI） of patients with schizophrenia. Method：Sixty-three patients with schizophrenia were randomized divided into two groups.The trial group were treated with quetiapine combined with aripiprazole group（31 cases） and the control group（32 cases） were treated with quetiapine only.Clinical efficacies were assessed with positive and negative syndrome scale（PANSS）and the body weight,abdomen circumference and BMI in patients were measured at the base line and at the end of the 6th week. Results：After the treatment of the 6th week,there were no significant difference in the scores of PANSS between the two groups（t=1.35,P0.05）.The abdomen circumference in the patients of the trial group became longer（t=7.76,P0.05）.The body weight,abdomen circumference and BMI in the the control group increased obviously（P0.05）.Compared with the trial group,the changes in controls increased obviously in body weight,abdomen circumference and BMI（P0.05）. Conclusion：Quetiapine combined with aripiprazole can obviously reduce the effects of quetiapine on body mass.